Curcumin for Gout

Curcumin has not been shown to help gout. In the one randomised, placebo-controlled trial aimed at uric acid, 39 adults with high uric acid took 1,000 mg of curcumin or a placebo daily for 8 weeks: serum urate fell by 6.9% on curcumin and 5.0% on placebo, and the difference was not significant (Bupparenoo 2021).

No trial has enrolled people with gout or counted flares. The idea that curcumin could ease flares rests on cell and rodent studies (Chen B 2019; Li 2019). For gout itself, guidelines recommend colchicine, NSAIDs or steroids for flares, and allopurinol as the first-line urate-lowering drug, aiming for a serum urate below 6 mg/dL (Richette 2017; FitzGerald 2020).

A gout flare starts when urate crystals set off inflammation in a joint. In human and mouse immune cells exposed to these crystals, curcumin blocked NF-kB signalling, protected mitochondria and reduced NLRP3 inflammasome activity, lowering inflammatory signals such as IL-1β, IL-6 and TNF-α (Chen B 2019). In rats with crystal-induced gouty arthritis, curcumin reduced joint swelling and neutrophil infiltration (Li 2019).

In mice made hyperuricaemic with potassium oxonate, curcumin given by mouth for 14 days lowered serum uric acid and xanthine oxidase, the enzyme that makes uric acid, and reduced kidney inflammation (Chen Y 2019). A 2025 mouse study reported lower uric acid and more ABCG2, a transporter that helps the kidneys clear urate (Zhao 2025). A 2024 review lists xanthine oxidase and URAT1 inhibition among curcumin's lab effects (Jafari-Nozad 2024).

Both crystal-inflammation studies gave curcumin by injection into the abdomen, not by mouth (Chen B 2019; Li 2019), so they say little about what a capsule does during a flare. The same 2024 review that lists the lab effects also notes that some studies found no notable fall in uric acid, and calls for well-designed trials before curcumin is accepted as a gout treatment (Jafari-Nozad 2024).

The trial's authors expected curcumin to lower urate by blocking xanthine oxidase and increasing uric acid excretion. They did not measure the enzyme itself; serum urate fell no more than with placebo, and urinary uric acid clearance did not differ between groups (Bupparenoo 2021).

No dose of curcumin has been shown to lower uric acid or prevent gout flares. The urate trial used 500 mg capsules twice daily (1,000 mg a day) for 8 weeks, without a benefit over placebo (Bupparenoo 2021). The fatty liver trial that reported lower uric acid also used 1,000 mg a day in two doses for 8 weeks (Panahi 2016).

Across arthritis trials, doses ranged from 120 to 1,500 mg for 4-36 weeks (Zeng 2022). Conventional curcumin is likely safe in recommended amounts for up to 2-3 months, but formulations made to absorb better have been linked to liver injury (NCCIH 2025; Lombardi 2021).

Bupparenoo and colleagues in Thailand randomised 39 adults with persistent asymptomatic hyperuricaemia (serum urate of at least 6 mg/dL in women or 7 mg/dL in men) to curcumin 500 mg twice daily or placebo for 8 weeks (Bupparenoo 2021).

Serum urate fell in both groups: by 6.9% with curcumin (p=0.002) and by 5.0% with placebo (p=0.009). The difference between the groups was not significant (p=0.532), and urinary uric acid clearance, fasting glucose and lipids did not change differently either. The authors concluded that curcumin was not superior to placebo (Bupparenoo 2021).

In a trial of 102 adults with fatty liver disease, 1,000 mg of curcumin a day for 8 weeks was associated with lower uric acid (P<0.001) along with lower cholesterol and triglycerides (Panahi 2016). A 6-month double-blind trial in type 2 diabetes also reported lower uric acid among many metabolic results (Chuengsamarn 2014). Neither abstract gives the size of the uric acid change, and neither enrolled people with gout.

When trials in diabetes were pooled, curcumin or turmeric showed only a non-significant trend toward lower uric acid (-1.46 mg/dL, 95% CI -2.93 to 0.02, p=0.053), with low certainty of evidence (Bahari 2026). A letter to the journal that published the urate trial warned that uric acid measurement in some 8-week curcumin trials was unreliable, with control groups changing significantly in both directions (McMullen 2021).

A 2026 meta-analysis of 21 polyphenol trials found that flavonoids lowered serum uric acid but curcuminoids showed non-significant effects (Xie 2026). A 2022 meta-analysis of curcumin across five types of arthritis included only one gout or hyperuricaemia trial, the null urate trial (Zeng 2022). A 2021 Cochrane review of supplements for chronic gout found just two eligible trials, neither of them of curcumin (Andres 2021).

What's missing: any trial in people with diagnosed gout, any trial counting flares, pain or tophi, and any comparison with allopurinol. For supplements with more gout data, see vitamin C, tart cherry and quercetin.

In the urate trial, adverse events were no more common with curcumin than with placebo; the most common was diarrhoea, which needed no treatment (Bupparenoo 2021). Conventional curcumin is likely safe in recommended amounts for up to 2-3 months, though it can cause nausea, reflux, diarrhoea or constipation. Turmeric supplements may be unsafe in pregnancy, and little is known about doses above food amounts while breastfeeding (NCCIH 2025). The European Medicines Agency does not recommend turmeric for people with bile-duct obstruction, cholangitis, liver disease, gallstones or other biliary disease, because it may stimulate bile secretion, and says its use under 18 has not been established (EMA 2019).

Liver injury is the main concern. The US Drug-Induced Liver Injury Network found 10 turmeric-associated cases, five of them hospitalised and one fatal, typically starting 1-4 months after starting the product; 3 of 7 tested products also contained piperine (Halegoua-DeMarzio 2023). Italian cases were linked to high-bioavailability, high-dose curcumin products, and most improved after stopping (Lombardi 2021). Turmeric in supplement doses also raised urinary oxalate in healthy adults, which may increase kidney stone risk in susceptible people (Tang 2008). If you have chronic kidney disease, see that page before trying curcumin.

A 2022 review found that in people taking anticoagulants, turmeric supplements are associated with bleeding risk (Hatfield 2022). Curcumin also changes drug-metabolising enzymes: in 16 healthy men, 1,000 mg a day for 14 days lowered CYP1A2 activity by 28.6% and raised CYP2A6 activity by 48.9% (Chen 2010). A review of curcumin interactions found mostly lab and animal evidence of changes in drug levels, including for anticoagulants and heart drugs, and advised caution (Bahramsoltani 2017).

We found no study testing curcumin together with allopurinol, febuxostat or colchicine, or with NSAIDs during a gout flare, so there are no data on these combinations either way. A 2022 review advises stopping non-essential supplements 2 weeks before surgery (Hatfield 2022).